Malignant hypertension--improving prognosis in a rare disease

Area of Science:

• Nephrology
• Cardiology
• Hypertension Research

Background:

• Malignant hypertension presents a significant clinical challenge with historically high mortality rates.
• Understanding long-term outcomes and prognostic factors is crucial for effective patient management.

Purpose of the Study:

• To evaluate the long-term survival rates and prognostic indicators in patients diagnosed with malignant hypertension.
• To assess the impact of renal function and antihypertensive treatment on outcomes.

Main Methods:

• A follow-up study of 69 patients diagnosed with malignant hypertension between 1969 and 1976.
• Analysis of patient demographics, hypertension type (essential vs. secondary), serum creatinine levels, treatment strategies, and survival data.

Main Results:

• Overall 5-year survival rates were 75% for essential and 72% for secondary malignant hypertension, showing improvement over previous series.
• Male predominance was observed, particularly in essential hypertension.
• Serum creatinine levels at diagnosis significantly impacted renal function preservation; levels below 300 mumol/l allowed maintenance or improvement with treatment, while higher levels showed progression despite therapy.
• Advances like hemodialysis and renal transplantation contributed to improved survival.
• A decreasing incidence of new malignant hypertension cases was noted over the observation period.

Conclusions:

• Malignant hypertension outcomes have improved, with significant 5-year survival rates.
• Preservation of renal function at diagnosis is a critical determinant of successful antihypertensive treatment.
• Aggressive management, including renal replacement therapies, plays a vital role in improving survival for malignant hypertension patients.